Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Uganda has been showing steady growth in recent years.
Customer preferences: Uganda's population is rapidly aging, which has led to an increase in the number of people suffering from cardiovascular diseases. As a result, there has been a growing demand for Anti-Coagulants in the country. Patients are also becoming more aware of the benefits of Anti-Coagulants in preventing blood clots, which has further fueled the demand.
Trends in the market: The Anti-Coagulants market in Uganda is dominated by multinational pharmaceutical companies. However, there has been an increase in the number of local manufacturers entering the market, which has led to increased competition. This has resulted in a drop in prices, making Anti-Coagulants more affordable for patients.
Local special circumstances: The healthcare system in Uganda is underdeveloped, with limited resources and infrastructure. This has led to a lack of access to healthcare services, particularly in rural areas. As a result, patients often have to travel long distances to access healthcare facilities. This has created a need for more affordable and accessible Anti-Coagulants, which has led to the entry of local manufacturers into the market.
Underlying macroeconomic factors: Uganda's economy has been growing steadily in recent years, with a focus on developing the healthcare sector. The government has been investing heavily in improving healthcare infrastructure and increasing access to healthcare services. This has led to an increase in the number of healthcare facilities and healthcare professionals in the country. As a result, there has been a growing demand for Anti-Coagulants to treat cardiovascular diseases. The government has also been promoting the use of generic drugs, which has led to increased competition in the Anti-Coagulants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
